Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient did not read the instructions properly and took all the four capsules of Vivotif at one time.; The patient did not read the instructions properly and took all the four capsules of Vivotif at one time.; Case reference number US-BN-2025-000924 is a spontaneous case initially received from nurse via agency (reference number: USBAV25-1073) on 09-May-2025 and concerns a 51-year-old female patient. The patient's medical history and concomitant medication details were not provided. On unspecified date, as reported, the patient did not read the instructions properly and took the all the four capsules of Vivotif at one time (batch number: unknown), at a dose of four capsule, orally, for typhoid immunization (explicitly coded as 'vaccine overdose' and 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A 51-year-old female patient did not read the instructions properly and took the all the four capsules of Vivotif at one time, at a dose of four capsule, orally, for typhoid immunization which is considered as vaccine overdose and inappropriate schedule of vaccine administered. Inappropriate schedule of product administration and overdose are considered listed per company conventions. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration and overdose are both assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 51-year-old female patient did not read the instructions properly and took the all the four capsules of Vivotif at one time, at a dose of four capsule, orally, for typhoid immunization which is considered as vaccine overdose and inappropriate schedule of vaccine administered. Inappropriate schedule of product administration and overdose are considered listed per company conventions. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration and overdose are both assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None